Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,794
Total Claims
$1.4M
Drug Cost
677
Beneficiaries
$2,085
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-5%
Opioid rate vs peers
2.5% vs 2.6% avg
+95%
Cost per patient vs peers
$2,085 vs $1,068 avg
+91%
Brand preference vs peers
17.2% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.5%
Opioid Rate
338
Opioid Claims
$18K
Opioid Cost
16.0%
Long-Acting Rate
Brand vs Generic
Brand: 2,344 claims · $1.1M
Generic: 11,300 claims · $291K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 276 | $130K |
| Empagliflozin | 124 | $99K |
| Semaglutide | 76 | $84K |
| Dulaglutide | 53 | $78K |
| Rivaroxaban | 132 | $55K |
| Sitagliptin Phosphate | 67 | $50K |
| Fluticasone/Umeclidin/Vilanter | 65 | $47K |
| Insulin Aspart | 49 | $38K |
| Dapagliflozin Propanediol | 55 | $36K |
| Linaclotide | 47 | $35K |
| Linagliptin | 43 | $35K |
| Insulin Glargine/Lixisenatide | 47 | $22K |
| Insulin Glargine,hum.Rec.Anlog | 71 | $22K |
| Insulin Degludec | 22 | $20K |
| Tirzepatide | 13 | $18K |
Prescribing Profile
Patient Profile
76
Avg Age
54%
Female
1.26
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About